Mutational and oxidative stress analysis in patients with mucopolysaccharidosis type I undergoing enzyme replacement therapy
- PMID: 17920576
- DOI: 10.1016/j.cca.2007.09.008
Mutational and oxidative stress analysis in patients with mucopolysaccharidosis type I undergoing enzyme replacement therapy
Abstract
Background: Mucopolysaccharidosis type I (MPS I) patients present a wide range of clinical manifestations, which could be due to the high molecular heterogeneity of the IDUA gene and to pathological events besides the enzyme deficiency. The aim of this study was to identify the most common MPS I causing mutations and to evaluate some oxidative stress markers in Brazilian patients.
Methods: 3 common mutations in the IDUA gene were searched in 11 MPS I patients by PCR-RFLP. Activities of antioxidant enzymes catalase and superoxide dismutase, and levels of total glutathione and thiobarbituric acid reactive substances were evaluated by spectrophotometric and colorimetric methods, during different periods of enzyme replacement therapy.
Results: The most common mutations were P533R and W402X, with allelic frequencies of 33.33% and 27.8% respectively. MPS I patients presented high levels of lipid peroxidation and enzyme replacement therapy led to an increase of catalase and a decrease of superoxide dismutase activities.
Conclusions: P533R and W402X accounted for more than 60% of the alleles, but no genotype-phenotype correlation could be established. The alterations in antioxidant enzyme activities suggest that oxidative stress may be an important event among MPS I patients, which could contribute to the physiopathology of the disease.
Similar articles
-
Identification and molecular characterization of alpha-L-iduronidase mutations present in mucopolysaccharidosis type I patients undergoing enzyme replacement therapy.Hum Mutat. 2004 Sep;24(3):199-207. doi: 10.1002/humu.20081. Hum Mutat. 2004. PMID: 15300847
-
alpha-L-iduronidase mutations (Q70X and P533R) associate with a severe Hurler phenotype.Hum Mutat. 1992;1(4):333-9. doi: 10.1002/humu.1380010412. Hum Mutat. 1992. PMID: 1301941
-
Molecular analysis of 30 mucopolysaccharidosis type I patients: evaluation of the mutational spectrum in Italian population and identification of 13 novel mutations.Hum Mutat. 2002 Sep;20(3):231. doi: 10.1002/humu.9051. Hum Mutat. 2002. PMID: 12203999
-
Molecular genetics of mucopolysaccharidosis type I: diagnostic, clinical, and biological implications.Hum Mutat. 1995;6(4):288-302. doi: 10.1002/humu.1380060403. Hum Mutat. 1995. PMID: 8680403 Review.
-
Can mucopolysaccharidosis type I disease severity be predicted based on a patient's genotype? A comprehensive review of the literature.Genet Med. 2003 Jul-Aug;5(4):286-94. doi: 10.1097/01.GIM.0000078027.83236.49. Genet Med. 2003. PMID: 12865757 Review.
Cited by
-
Reactive Oxygen Species and Oxidative Stress in the Pathogenesis and Progression of Genetic Diseases of the Connective Tissue.Antioxidants (Basel). 2020 Oct 19;9(10):1013. doi: 10.3390/antiox9101013. Antioxidants (Basel). 2020. PMID: 33086603 Free PMC article. Review.
-
CASE SERIES OF PATIENTS UNDER BIWEEKLY TREATMENT WITH LARONIDASE: A REPORT OF A SINGLE CENTER EXPERIENCE.Rev Paul Pediatr. 2019 May 9;37(3):312-317. doi: 10.1590/1984-0462/;2019;37;3;00010. eCollection 2019. Rev Paul Pediatr. 2019. PMID: 31090850 Free PMC article.
-
The Inflammation in the Cytopathology of Patients With Mucopolysaccharidoses- Immunomodulatory Drugs as an Approach to Therapy.Front Pharmacol. 2022 May 13;13:863667. doi: 10.3389/fphar.2022.863667. eCollection 2022. Front Pharmacol. 2022. PMID: 35645812 Free PMC article. Review.
-
New treatments for the mucopolysaccharidoses: from pathophysiology to therapy.Ital J Pediatr. 2018 Nov 16;44(Suppl 2):124. doi: 10.1186/s13052-018-0564-z. Ital J Pediatr. 2018. PMID: 30442204 Free PMC article. Review.
-
Mucopolysaccharidosis: What Pediatric Rheumatologists and Orthopedics Need to Know.Diagnostics (Basel). 2022 Dec 27;13(1):75. doi: 10.3390/diagnostics13010075. Diagnostics (Basel). 2022. PMID: 36611367 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical